|Master Investor Magazine
Never miss an issue of Master Investor Magazine – sign-up now for free!
The price of shares in AIM-listed Scapa (LON:SCPA) is up by 12.01% to 354.50p (as of 12:55 BST) after it announced a 7% increase in revenues for the year ended 31st March, driven by the company’s healthcare arm. Trading profits and margins are in line with expectations.
Chief executive Heejae Chae said: “We reached a milestone of £300 million in revenue and delivered a record profit. In Industrial, we continue to focus on margin improvement and cash generation to support future growth. In Healthcare, the technology transfer of Systagenix’s R&D and manufacturing capabilities from a strategic partner and customer was a transformative transaction. It has enhanced the foundations of our Healthcare strategy and provides the capabilities to deliver long-term sustainable growth as we continue to expand our offering across the complete value chain“.